DOCSLIB.ORG

FEI Prohibited Substances List 20Oct09-Sentnfs17dec09.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FEI Prohibited Substances List 20Oct09-Sentnfs17dec09.Xlsx Prohibited Substances List This is the Equine Prohibited Substances List that was sent out to all NFs on 20 October. Neither this List nor the Equine Anti-Doping and Controlled Medication Regulations (EADCMR) are in current usage and, following a Bureau resolution passed on 18 December 2009, they will come into effect on 5 April 2010. The existing list of FEI prohibited substances, which remains in effect until then, can be found at Annex II Vet Regs (11th edition). SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 38 Amineptine Tricyclic antidepressant 39 Aminoglutehthamide Aromatase inhibitor 40 Aminoheptane Vasopressor 41 Aminomethylbenzoic acid Anti-fibrinolytic 42 Aminopicoline Nitric oxide synthase inhibitor 43 Aminopromazine Antispasmodic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was sent out to all NFs on 20 October. Neither this List nor the Equine Anti-Doping and Controlled Medication Regulations (EADCMR) are in current usage and, following a Bureau resolution passed on 18 December 2009, they will come into effect on 5 April 2010. The existing list of FEI prohibited substances, which remains in effect until then, can be found at Annex II Vet Regs (11th edition). SUBSTANCE ACTIVITY 44 Aminopterin Immunosuppressant 45 Amiodarone Antiarrythmic 46 Amiphenazole Stimulant 47 Amisometradine Diuretic 48 Amisulpride Antipsychotic 49 Amitriptylline Tricyclic antidepressant 50 Amlodipine Antihypertensive 51 Amobarbital Sedative 52 Amodiaquine Antimalarial 53 Amopyroquine Antimalarial 54 Amoxapine Tricyclic antidepressant 55 Amperozide Antipsychotic 56 Amphetamine Stimulant 57 Amphetaminil Stimulant 58 Ampyrone NSAID 59 Amrinone Vasodilator 60 Amyl nitrate/nitrite Angina treatment 61 Amylocaine Local anaesthetic 62 Anastrozole Aromatase inhibitor 63 Androstenediol Anabolic 64 Androstenedione Anabolic 65 Anileridrine Opiod analgesic 66 Anilopam CNS stimulant 67 Anisindione Anticoagulant 68 Anisotropine Anticholinergic 69 Antazoline Antihistamine 70 Antipyrine NSAID 71 Apazone (azapropazone) NSAID 72 Apocodeine Opiod analgesic 73 Apomorphine Opiod analgesic 74 Aprindine Antiarrythmic 75 Aprobarbital Sedative 76 Apronalide Sedative 77 Arecoline Stimulant 78 Arformoterol Bronchodilator 79 Arsenic Stimulant/toxic 80 Articaine Local anaesthetic 81 Atenolol Beta Blocker 82 Atomoxetine Selective noradrenaline reuptake inhibitor 83 Atracurium Muscle relaxant 84 Azacyclonal Antipsychotic 85 Azaperone Sedative 86 Azapetine Vasodilator 87 Azapropazone NSAID 88 Azatadine Antihistamine 2 Prohibited Substances List This is the Equine Prohibited Substances List that was sent out to all NFs on 20 October. Neither this List nor the Equine Anti-Doping and Controlled Medication Regulations (EADCMR) are in current usage and, following a Bureau resolution passed on 18 December 2009, they will come into effect on 5 April 2010. The existing list of FEI prohibited substances, which remains in effect until then, can be found at Annex II Vet Regs (11th edition). SUBSTANCE ACTIVITY 89 Azathioprine Immunosuppressant 90 Baclofen Antispasmodic 91 Bambuterol Bronchodilator 92 Bamifylline Bronchodilator 93 Barbital Sedative 94 Beclamide Sedative 95 Bemegride Stimulant 96 Benactyzine Anticholinergic 97 Benapryzine Anticholinergic 98 Benazepril Antihypertensive 99 Bendroflumethazide Diuretic 100 Benorilate NSAID 101 Benoxaprofen NSAID 102 Benoxinate Local anaesthetic 103 Benperidol Antipsychotic 104 Bentazepam Anxiolytic 105 Benxylpiperazine Stimulant 106 Benzoctamine Sedative 107 Benzonatate Antitussive 108 Benzoylecgonine Stimulant/cocaine metabolite 109 Benzphetamine Stimualnt 110 Benzquinamide Antihistamine 111 Benzthiazide Diuretic 112 Benztropine Anticholinergic 113 Benzydamine NSAID 114 Benzylpiperazine Stimulant 115 Bepridil Calcium channel blocker 116 Betaprodine Opiod analgesic 117 Betaxolol Beta blocker 118 Bethanidine Antihypertensive 119 Biperiden Anticholinergic 120 Biphenamine NSAID 121 Biriperone Antipsychotic 122 Bisoprolol Beta blocker 123 Bitolterol Bronchodilator 124 Bolandiol Anabolic 125 Bolasterone Anabolic 126 Boldenone Anabolic 127 Boldione Anabolic 128 Bretylium Antiarrythmic 129 Brimonidine Occular antihypertensive 130 Brinzolamide Diuretic 131 Bromantan Stimulant 132 Bromazepam Anxiolytic 133 Bromfenac NSAID 3 Prohibited Substances List This is the Equine Prohibited Substances List that was sent out to all NFs on 20 October. Neither this List nor the Equine Anti-Doping and Controlled Medication Regulations (EADCMR) are in current usage and, following a Bureau resolution passed on 18 December 2009, they will come into effect on 5 April 2010. The existing list of FEI prohibited substances, which remains in effect until then, can be found at Annex II Vet Regs (11th edition). SUBSTANCE ACTIVITY 134 Bromisovalum Sedative 135 Bromocriptine Dopamine agonist 136 Bromophenethylamine Psychedelic 137 Bromperidol Antipsychotic 138 Brompheniramine Antihistamine 139 Brotizolam Anxiolytic 140 Bucetin Analgesic/antipyretic 141 Buclizine Antihistamine 142 Budesonide Corticosteroid 143 Bufexamac NSAID 144 Buflomedil Vasoactive agent 145 Bufotenine Naturally occurring hallucinogen 146 Bumetanide Diuretic 147 Bunitrolol Beta adrenergic antagonist 148 Bunolol Beta blocker 149 Buphenine (Nylidrin) Sympathomimetic 150 Bupranolol Beta blocker 151 Bupropion Antidepressant 152 Buspirone Anxiolytic 153 Butabarbital Sedative 154 Butacaine Local anaesthetic 155 Butalbital Sedative 156 Butamben Nerve blocker 157 Butanilicaine Local anaesthetic 158 Butaperazine Antipsychotic 159 Butoctamide Serotonin release stimulation 160 Butofilolol Beta blocker 161 Butoxycaine Local anaesthetic 162 Cafedrine Analeptic 163 Calusterone Anabolic 164 Camazepam Anxiolytic 165 Candesartan Antihypertensive 166 Cannabis (or synthetic cannabinoids) Psychotropic 167 Canrenone Diuretic 168 Capsaicin Topical analgesic/irritant 169 Captodiame Anxiolytic 170 Captopril ACE inhibitor 171 Caramiphen Anticholinergic 172 Carazolol Beta blocker 173 Carbachol Parasympathomimetic 174 Carbapentane (pentoxyverine) Antitussive 175 Carbazochrome Haemostatic 176 Carbetapentane (Pentoxyverine) Antitussive 177 Carbidopa DOPA decarboxylase inhibitor 178 Carbimazole Antihyperthyroidism 4 Prohibited Substances List This is the Equine Prohibited Substances List that was sent out to all NFs on 20 October. Neither this List nor the Equine Anti-Doping and Controlled Medication Regulations (EADCMR) are in current usage and, following a Bureau resolution passed on 18 December 2009, they will come into effect on 5 April 2010. The existing list of FEI prohibited substances, which remains in effect until then, can be found at Annex II Vet Regs (11th edition). SUBSTANCE ACTIVITY 179 Carbinoxamine Antihistamine 180 Carbocysteine Mucoactive 181 Carbromal Sedative 182 Carbuterol Bronchodilator 183 Carfentanil Opiod analgesic 184 Carisoprodol Muscle relaxant 185 Carphedon Nootropic agent 186 Carphenazine Antipsychotic 187 Carpipramine Anxiolytic 188 Carteolol Beta blocker 189 Carticaine Local anaesthetic 190 Carvedilol Beta blocker 191 Cathine (norpseudoephedrine) Stimulant 192 Celecoxib NSAID 193 Celiprolol Beta blocker 194 Cephaeline Emetic 195 Chloral betaine Sedative 196 Chloral hydrate Sedative 197 Chloralbutanol Topical analgesic 198 Chlorcyclizine Antihistamine 199 Chlordiazepoxide Anxiolytic 200 Chlormerodrin Diuretic 201 Chlormethiazole Sedative 202 Chlormezanone Anxiolytic 203 Chloroform Sedative 204 Chlorophenesin Muscle relaxant 205 Chlorophenyl piperazine Psychoactive 206 Chloroprocaine Local anaesthetic 207 Chloropyramine Antihistamine 208 Chloroquine Antimalarial 209 Chlorphenoxamine Antipruritic 210 Chlorphentermine Stimulant 211 Chlorproethazine Antihistamine 212 Chlorpromazine Sedative 213 Chlorpropamide Antidiabetic 214 Chlorprothixene Antipsychotic 215 Chlorthalidone Diuretic 216 Chlorthenoxazine Antipruritic 217 Chlorzoxazone Muscle relaxant 218 Chromoglycate Antihistamine 219 Ciclesonide Corticosteroid 220 Cicloprofen NSAID 221 Cilazapril Antihypertensive 222 Cilostazol Vasodilator 223 Cimaterol Beta agonist 5 Prohibited Substances List This is the Equine Prohibited Substances List that was sent out to all NFs on 20 October. Neither this List nor the Equine Anti-Doping and Controlled Medication Regulations (EADCMR) are in current usage and, following a Bureau resolution passed on 18 December 2009, they will come into effect on 5 April 2010. The existing list of
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 5,955,504 Wechter Et Al
    USOO5955504A United States Patent (19) 11 Patent Number: 5,955,504 Wechter et al. (45) Date of Patent: Sep. 21, 1999 54 COLORECTAL CHEMOPROTECTIVE Marnett, “Aspirin and the Potential Role of Prostaglandins COMPOSITION AND METHOD OF in Colon Cancer, Cancer Research, 1992; 52:5575–89. PREVENTING COLORECTAL CANCER Welberg et al., “Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A 75 Inventors: William J. Wechter; John D. Refined Immunohistochemical Method.” J. Clin Pathol, McCracken, both of Redlands, Calif. 1990; 43:453-456. Thun et al., “Aspirin Use and Reduced Risk of Fatal Colon 73 Assignee: Loma Linda University Medical Cancer." N Engl J Med 1991; 325:1593-6. Center, Loma Linda, Calif. Peleg, et al., “Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer.” 21 Appl. No.: 08/402,797 Arch Intern Med. 1994, 154:394–399. 22 Filed: Mar 13, 1995 Gridley, et al., “Incidence of Cancer among Patients With Rheumatoid Arthritis J. Natl Cancer Inst 1993 85:307-311. 51) Int. Cl. .......................... A61K 31/19; A61K 31/40; Labayle, et al., “Sulindac Causes Regression Of Rectal A61K 31/42 Polyps. In Familial Adenomatous Polyposis” Gastroenterol 52 U.S. Cl. .......................... 514/568; 514/569; 514/428; ogy 1991 101:635-639. 514/416; 514/375 Rigau, et al., “Effects Of Long-Term Sulindac Therapy On 58 Field of Search ..................................... 514/568, 570, Colonic Polyposis” Annals of Internal Medicine 1991 514/569, 428, 416, 375 11.5:952-954. Giardiello.et al., “Treatment Of Colonic and Rectal 56) References Cited Adenomas With Sulindac In Familial Adenomatous Poly U.S.
    [Show full text]
  • Solid Solution Compositions and Use in Chronic Inflammation
    (19) *EP003578172A1* (11) EP 3 578 172 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.12.2019 Bulletin 2019/50 A61K 9/14 (2006.01) A61K 47/14 (2017.01) A61K 47/44 (2017.01) A61K 31/12 (2006.01) (2006.01) (2006.01) (21) Application number: 19188174.7 A61K 31/137 A61K 31/167 A61K 31/192 (2006.01) A61K 31/216 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.01.2014 A61K 31/357 A61K 31/366 A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) A61K 31/522 (2006.01) A61K 31/616 (2006.01) A61K 31/196 (2006.01) (84) Designated Contracting States: • BREW, John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB London, Greater London EC2Y 8AD (GB) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • REILEY, Richard Robert PL PT RO RS SE SI SK SM TR London, Greater London EC2Y 8AD (GB) • CAPARRÓS-WANDERLEY, Wilson (30) Priority: 14.01.2013 US 201361752356 P London, Greater London EC2Y 8AD (GB) 04.02.2013 US 201361752309 P (74) Representative: Clements, Andrew Russell Niel et (62) Document number(s) of the earlier application(s) in al accordance with Art. 76 EPC: Schlich 14702460.8 / 2 925 367 9 St Catherine’s Road Littlehampton, West Sussex BN17 5HS (GB) (71) Applicant: InFirst Healthcare Limited London EC2Y 8AD (GB) Remarks: This application was filed on 24-07-2019 as a (72) Inventors: divisional application to the application mentioned • BANNISTER, Robin Mark under INID code 62.
    [Show full text]
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs Inhibit Bone Healing: a Review S
    Review Article © Schattauer 2010 385 Non-steroidal anti-inflammatory drugs inhibit bone healing: A review S. Barry Washington State University, Department of Veterinary Clinical Sciences, Veterinary Teaching Hospital, Pullman, Wash- ington, USA crine and autocrine activity, have since Keywords stems from prostaglandin inhibition and is been shown to regulate constitutive and in- Non-steroidal anti-inflammatory drugs, likely multifactorial. In human medicine ducible functions throughout the body, in- NSAID, bone healing NSAID are known to prevent heterotopic ossi- cluding bone healing (5–9). The mech- fication, however the clinical importance of anism of NSAID inhibition to bone healing Summary their effects on bone healing remains contro- is unknown, but is likely multifactorial. Re- The ability of non-steroidal anti-inflammatory versial. Although a small handful of reports searchers have suggested that NSAID affect drugs (NSAID) to inhibit bone healing has suggest that NSAID suppress bone healing in normal bone healing in multiple ways, with been established in experimental animal dogs and horses, there is little published infor- emphasis often (but not exclusively) placed models using mice, rats, and rabbits. The mation to direct veterinary practice in do- on processes related to the inflammatory mechanism of action is largely unknown but mestic species. stage. Deciphering the mechanism of NSAID inhibition requires an understanding of Correspondence to: Vet Comp Orthop Traumatol 2010; 23: 385–392 Sabrina Barry, DVM doi:10.3415/VCOT-10-01-0017 fracture healing. Fracture healing presents Washington State University Received: January 31, 2010 an exquisitely orchestrated series of coor- Department of Veterinary Clinical Sciences Accepted: June 23, 2010 dinated molecular and cellular events.
    [Show full text]
  • Latest Administration Hour Prior to Competition Max Dosage Per Pound of Body Weight Medication Trade Name Medication Generic Name
    MEDICATION MEDICATION MAX DOSAGE PER POUND LATEST ADMINISTRATION HOUR ADMINISTRATION METHOD GENERIC NAME TRADE NAME OF BODY WEIGHT PRIOR TO COMPETITION (single dose per 24 hours unless specified otherwise) Dexamethasone Azium® 2.0 mg/100Lb >12 hours IV, IM (20 mg/1000Lb) or 0.5 mg/100Lb >6 hours IV (5.0 mg/1000Lb) or 1.0 mg/100LB >6 hours Oral (10 mg/1000Lb) Diclofenac Surpass® 5 inch ribbon, 1⁄2 inch thick, >12 hours Topical, 2 doses each day 12 hours apart one site Firocoxib Equioxx® 0.1 mg/kg >12 hours Oral (0.0455 mg/Lb) (45.5 mg/1000Lb) Phenylbutazone (“bute”) * Butazolidin® 2.0 mg/Lb >12 hours Oral, IV (2.0 grams/1000Lb) or 1.0 mg/Lb AM & PM feed Oral, 2 doses each day, 12 hours apart (1.0 grams/1000Lb) Flunixin meglumine * Banamine® 0.5 mg/Lb >12 hours Oral, IV (500 mg/1000Lb) Ketoprofen Ketofen® 1.0 mg/Lb >4 hours, but IV (1.0 gram/1000Lb) >6 hours is recommended Meclofenamic acid Arquel® 0.5 mg/Lb Oral, 2 doses each day, 12 hours apart (500 mg/1000Lb) Naproxen Naprosyn® 4.0 mg/Lb >12 hours Oral (4.0 grams/1000Lb) Eltenac Not yet approved Telzenac® 0.25 mg/Lb (250 mg/1000Lb) 12 hours IV Methocarbamol Robaxin® 5.0 mg/Lb >6 hours Oral, IV, 2 doses each day, 12 hours apart (5.0 grams/1000Lb) * Do not administer phenylbutazone and flunixin at the same time (Unless used according to The maximum treatment time for any of the above permitted medication is five days, with the Section 8).
    [Show full text]
  • Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle By
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Food Anal. Methods (2016) 9:1837–1848 DOI 10.1007/s12161-015-0352-y Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle by Liquid Chromatography-Tandem Mass Spectrometry Piotr Jedziniak1 & Małgorzata Olejnik1 & Konrad Pietruk1 & Edyta Protasiuk1 & Teresa Szprengier-Juszkiewicz1 & Jan Żmudzki1 Received: 11 February 2015 /Accepted: 4 November 2015 /Published online: 21 November 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract A method for the determination of a wide range Introduction residues of anti-inflammatory drugs (16 acidic non-steroidal anti-inflammatory drugs and four metamizole metabolites and Non-steroidal anti-inflammatory drugs (NSAIDs) and five corticosteroids) has been was developed. In the first step glucocorticosteroids (GCs) are widely used in veterinary medi- of sample preparation, acetate buffer was added to minced cine as well as in treatment of diseases in food-producing ani- muscle samples and 15-min ultrasound-assisted enzymatic mals. Despite its effectiveness, the important drawback of phar- hydrolysis was performed. Next, the samples were extracted macotherapy is drug residues in animal tissues. It became an twice with acetonitrile, freezed and analysed. The analytes important issue in the food safety. Potential toxicity of medicinal were separated on a C18 column with a 25-min gradient of veterinary products has to be evaluated before the drug registra- methanol/acetonitrile (8:2) and 0.05 M ammonium formate at tion. When necessary, maximum residue limits (MRLs) in food pH 5.0 and determined by liquid chromatography-tandem are established.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs As Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals
    Annual Research & Review in Biology 26(1): 1-13, 2018; Article no.ARRB.40829 ISSN: 2347-565X, NLM ID: 101632869 Non-Steroidal Anti-Inflammatory Drugs as Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals Bianca F. Bishop1 and Suong N. T. Ngo1* 1School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia. Authors’ contributions This work was carried out in collaboration between both authors. Author BFB performed the collection and analysis of the data. Author SNTN designed the study, managed the analyses and interpretation of the data and prepared the manuscript. Both authors read and approved the final manuscript. Article Information DOI: 10.9734/ARRB/2018/40829 Editor(s): (1) David E. Martin, Martin Pharma Consulting, LLC, Shawnee, OK, USA. (2) George Perry, Dean and Professor of Biology, University of Texas at San Antonio, USA. Reviewers: (1) Fulya Ustun Alkan, Istanbul University, Turkey. (2) Thompson Akinbolaji, USA. (3) Ramesh Gurunathan, Sunway Medical Center, Malaysia. (4) Mohamed Ahmed Mohamed Nagy Mohamed, El Minia Hospital, Egypt. Complete Peer review History: http://www.sciencedomain.org/review-history/24385 Received 10th February 2018 Accepted 21st April 2018 Review Article Published 30th April 2018 ABSTRACT Aims: This study aims to systematically review currently available data on the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of cancer in domestic animals to evaluate the efficacy of different treatment protocols and to suggest further recommendations for future study. Methodology: Literature data on the use of NSAIDs in domestic animals as chemo-preventive agents in the last decade were collected and critically reviewed.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Transitional Cell Carcinoma: Options Beyond Nsaids Julie Marie Gillem, DVM, DACVIM (Oncology) Overview
    Transitional Cell Carcinoma: Options Beyond NSAIDs Julie Marie Gillem, DVM, DACVIM (Oncology) Overview ✦ Background ✦ Surgical Options ✦ Pathology ✦ Medical Options ✦ Location and staging ✦ Radiation Therapy ✦ Behavior Options ✦ Etiology and risk factors ✦ Palliative care ✦ Work up and diagnosis ✦ What about cats? Objectives ✦ How do we determine when NSAIDs fail? ✦ When should we intervene with surgery, chemotherapy, radiation therapy, and additional palliative care? Pathology ✦ ~2% of canine cancer ✦ Invasive transitional cell carcinoma (TCC) most common ✦ Others: SCC, adenocarcinoma, undifferentiated carcinoma, rhabdomyosarcoma, fibroma, and other mesenchymal tumors Location and Staging ✦ TCC in dogs most often found in the trigone of the bladder ✦ Series of 102 dogs at PUVTH ✦ Urethra and bladder in 56% ✦ Prostate involvement in 29% male dogs ✦ Lymph node mets in 16% at diagnosis ✦ Distant mets in 14% at diagnosis ✦ Distant mets in 50% at death Location ✦ TCC in dogs most often is found in the trigone region of the bladder. ✦ In a series of dogs with TCC examined at the PUVTH, the tumor involved the urethra as well as the bladder in 57 of 102 dogs (56%), and it involved the prostate in 11 of 38 (29%) male dogs. WHO Staging ✦ 78% T2 tumors ✦ 20% T3 tumors Biological Behavior ✦ At diagnosis: ✦ Regional lymph node metastasis in 12-46 % (Norris et al 1992, Knapp et al 2000, Blackburn et al 2013) ✦ Distant metastasis in 16- 23% (Norris et al 1992, Blackburn et al 2013) ✦ Distant metastasis in 50% at death (Norris et al 1992, Knapp et al
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]